Cytosorbents Corp Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cytosorbents Corp (Nevada) on January 7, 2014, reporting events occurring on December 31, 2013. The filing primarily addresses the execution of employment agreements with key executive officers.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on executive compensation rather than financial performance metrics.
Material Changes
The material change reported is the formalization of employment terms for two principal officers, retroactively effective as of January 1, 2013:
- Dr. Phillip P. Chan: Reappointed as Chief Executive Officer (CEO) and President. The agreement has a one-year term with an initial base compensation of $245,386.
- Vincent Capponi: Reappointed as Chief Operating Officer (COO). The agreement has a one-year term with an initial base compensation of $239,445.
Both agreements include standard benefits (insurance, expenses, vacation, bonuses) and contain non-disclosure and one-year non-compete clauses within the United States and specified foreign areas.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on market conditions, or specific risk factors beyond the standard non-compete restrictions outlined in the employment contracts.
Investor Verification Checklist
- Verify the full terms of the employment agreements filed as Exhibits 10.1 and 10.2.
- Confirm the retroactive effective date of January 1, 2013, for compensation purposes.
- Review the specific foreign countries and areas listed in Section 5.2 of the agreements regarding non-compete restrictions.
- Check subsequent filings for any updates to executive compensation or tenure.